LANTUS AND LEVEMIR TO BE LISTED ON PBS
Posted on Monday, 4 September 2006
Member for Pearce and Chair of the Parliamentary Diabetes Support Group (PDSG) Hon Judi Moylan MP today announced that Lantus® (insulin glargine) and Levemir® (insulin detemir) will be available on the Pharmaceutical Benefits Scheme (PBS) from 1 October this year, for the treatment of patients with diabetes.
“Lantus® and Levemir® will be used to maintain a basic insulin level and are expected to reduce the incidence of episodes of low blood-sugar levels, or hypos. Both drugs have been recommended for Type 1 diabetes and Lantus® has also been recommended for Type 2 diabetes,” says Ms Moylan.
The Parliamentary Diabetes Support Group, chaired by Judi Moylan MP, has supported the listing of long acting insulin and worked closely with Government and industry. Some of their other achievements include –
• The listing of insulin pump consumables on the National Diabetes Services Scheme (NDSS) in 2004;
• Medicare rebates for Diabetes Educators for eligible patients;
• the launch of the 3rd edition of the Diabetes in the School information pack;
• the announcement of the Healthy School Communities Program by the Prime Minister in 2004, as part of the Healthy Active Program which is tackling obesity in schools;
• launching a new website for young people with Type 1 Diabetes - www.diabeteskidsandteens.com.au; and
• the commitment of $32 million over five years for the establishment of the Islet Cell Transplantation Centre during the 2005 Federal Budget. This centre will be run by the Juvenile Diabetes Research Foundation.
It is estimated that around 110,000 people will begin treatment with Lantus® or Levemir® in the first full year of listing, for Type 1 and Type 2 diabetes.
Further information is available at www.health.gov.au